New triple-drug combo shows promise for hard-to-treat leukemia patients

NCT ID NCT05155709

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called siremadlin added to two existing drugs (venetoclax and azacitidine) for adults with acute myeloid leukemia (AML) who are too frail for standard chemotherapy. The study included 14 people whose cancer did not respond well to initial treatment or who had high-risk features at diagnosis. The main goals were to find a safe dose and see if the combination could improve remission rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    Hong Kong, 999077, Hong Kong

  • Novartis Investigative Site

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    Beersheba, 8457108, Israel

  • Novartis Investigative Site

    Jerusalem, 9112001, Israel

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Alor Star, Kedah, 05460, Malaysia

  • Novartis Investigative Site

    Kuala Selangor, 68000, Malaysia

  • Novartis Investigative Site

    Izmir, Balcova, 35340, Turkey (Türkiye)

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

  • Texas Oncology Sammons Cancer Center

    Dallas, Texas, 78246, United States